Pulmatrix, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 28, 2024. This is an annual report, not a standalone fourth-quarter filing. Pulmatrix is a clinical-stage biopharmaceutical company developing inhaled therapies using its iSPERSE dry-powder platform. It had no approved products or product-sales revenue.
Financial results and liquidity
Amounts below are in millions of dollars except per-share data. Revenue was primarily collaboration revenue from Cipla for PUR1900, not product sales.
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $7.298 | $6.071 | +$1.227 |
| Research and development expense | $15.518 | $18.240 | −$2.722 |
| General and administrative expense | $6.520 | $6.778 | −$0.258 |
| Operating loss | $(14.740) | $(18.947) | Loss narrowed $4.208 |
| Net loss | $(14.121) | $(18.836) | Loss narrowed $4.715 |
| Basic and diluted net loss per share | $(3.87) | $(5.46) | — |
| Operating cash flow | $(15.985) | $(19.356) | Cash use decreased |
- Cash and cash equivalents were $19.173 million at year-end, versus $35.628 million a year earlier; cash, cash equivalents and restricted cash totaled $20.645 million. Net cash decreased $16.608 million during 2023.
- Total assets were $33.958 million; current assets were $20.843 million and current liabilities $3.909 million. Total liabilities were $15.963 million, including $8.756 million of operating lease liabilities. The filing does not report material borrowings at year-end.
- Accumulated deficit was $287.597 million. No income tax expense was recorded. The filing does not present a product gross margin; the company has no product sales.
- Management stated that year-end cash was expected to fund operations for at least 12 months after the filing and into the first quarter of 2026, based on current plans, spending prioritization and the Cipla amendment. This is a projection, not a guarantee.
Changes and business developments
- Revenue increased 20% year over year, attributed to higher activity under the Cipla agreement. One customer accounted for 100% of 2023 revenue and accounts receivable, creating significant concentration risk.
- R&D spending fell primarily due to lower PUR3100, PUR1800 and employee costs, partly offset by higher PUR1900 spending. G&A declined modestly.
- PUR3100: The FDA accepted the IND and issued a “study may proceed” letter in September 2023 for a Phase 2 acute-migraine study. The study remains dependent on financing or a partnership. Phase 1 results reported by the company showed five-minute peak exposure and fewer gastrointestinal effects than IV DHE; efficacy in migraine patients has not yet been established.
- PUR1800: Phase 1b testing in 18 stable COPD patients showed tolerability and no observed safety signals. The company is seeking a partner or other path to advance it; a Phase 2 study has not started.
- PUR1900: Under a January 6, 2024 amendment with Cipla, enrollment in Pulmatrix’s Phase 2b study was stopped at eight subjects. The decision was not attributed to safety concerns. The company expected to wind down study activities by July 30, 2024. Cipla will fund development and commercialization outside the United States after the wind-down; Pulmatrix may receive 2% royalties on potential ex-U.S. net sales. The parties will seek to monetize PUR1900 in the United States.
- The new Bedford headquarters lease commenced in August 2023 and has a ten-year noncancellable term. Future lease payments total $14.602 million before $5.846 million of imputed interest.
Outlook, risks and other notable items
- Management expects continuing operating losses and substantial development expenses. It is exploring financing or partnership arrangements for PUR3100 and partnerships for PUR1800. If funding or strategic arrangements are unavailable, Pulmatrix may need to reduce or delay development spending.
- Capital sufficiency depends on assumptions that may prove incorrect. Additional financing may be difficult or dilutive; the company warns that failure to obtain funding could force curtailment of programs or threaten continued operations.
- Other key risks include clinical and regulatory failure, reliance on collaborators and contract manufacturers, intellectual-property challenges, competition, and Nasdaq listing compliance. The Cipla collaboration is the sole source of reported revenue.
- The audit firm gave an unqualified opinion on the financial statements. Management concluded internal control over financial reporting was effective; the auditor was not engaged to audit or opine on those controls.
- No material legal proceedings were reported. The filing reports no cybersecurity incident that had materially affected results or financial condition.
Most important facts for investors to verify
- Whether Pulmatrix secures financing or a partner and actually begins the PUR3100 Phase 2 study; the reported runway is based on management assumptions.
- Cash burn, cash balance and financing activity after December 31, 2023, including potential dilution and any changes to the stated runway.
- Completion and costs of the PUR1900 wind-down, the terms and progress of any U.S. monetization, and Cipla’s development plans and royalty conditions outside the United States.
- Whether PUR1800 attracts a partner and advances beyond Phase 1b, and whether future clinical data support efficacy as well as safety.
- Revenue recognition estimates and the remaining Cipla deferred revenue: $4.3 million related to unsatisfied obligations at year-end, including $0.6 million current. The auditor identified estimated total contract costs for revenue recognition as a critical audit matter.